A White Paper Exclusive
By Alfred Doig and Susan Dana Jones, Ph.D., BioProcess Technology Consultants, Inc.
Getting products onto the market as quickly as possible still remains a key driver in the development of recombinant therapeutic proteins. Any advance in bioprocessing is of particular interest to the industry if it significantly shortens the development timeline or improves the end product. Even better are advances that do both. In the monoclonal antibody (MAb) area, platform processes have enabled companies to standardize on specific mammalian cell lines, transfection approaches, process conditions and downstream processing to shorten the development timeframe.
Access an exclusive white paper to read about several interesting trends in two development areas, which have the potential to shorten the development timeline still further.
Share this article with your social network, just click below to share now!